Fanzhang Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fanzhang Meng has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Chen Li
Department of Dermatology The First Affiliated Hospital (Shenzhen People's Hospital) School of Medicine Southern University of Science and Technology Shenzhen China
11 shared publications - Xiujuan Hou
Department of Rheumatology, Dongfang Hospital Beijing University of Chinese Medicine Beijing China
7 shared publications Tangliang Qian
Department of Rheumatology Dongfang Hospital Beijing University of Chinese Medicine Beijing China
4 shared publicationsZhimin Lin
Beijing University of Chinese Medicine Beijing China
4 shared publications- Di Jin
Department of Rheumatology Weifang People's Hospital Weifang China
3 shared publications Naigang Chen
Department of Medical Imaging, Fangshan Hospital Beijing University of Chinese Medicine Beijing China
3 shared publications
Latest Publications
- 1 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70788
Chronic Non‐Bacterial Osteitis Initially Attributed to Knee Osteoarthritis in an Older Adult: Bone Scintigraphy and MRI Findings
- 1 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70788
Chronic Non‐Bacterial Osteitis Initially Attributed to Knee Osteoarthritis in an Older Adult: Bone Scintigraphy and MRI Findings
- 28 August 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70825
Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients
Objective: This study aimed to evaluate the efficacy and safety of upadacitinib administered over a short‐term period in patients with SAPHO syndrome. Methods: In this 12‐week retrospective observational study, eligible SAPHO syndrome patients diagnosed within the past year and treated with upadacitinib were enrolled. Efficacy was assessed using the Ankylosing Spondylitis Disease Activity Score based on C‐reactive protein (ASDAS‐CRP) and the Palmoplantar Pustulosis Area and Severity Index (PPPASI). Safety was evaluated based on the incidence of adverse events during the treatment period. Results: A total of 35 eligible patients were included. Both ASDAS‐CRP and PPPASI scores decreased rapidly by Week 4 (−1.01 and −11.41, respectively; both p < 0.001) and showed further significant improvements at Week 12 (−1.50 and −14.69, respectively; both p < 0.001) compared to baseline. Similar improvements were observed in the Visual Analogue Scale for overall musculoskeletal pain, the Bath Ankylosing Spondylitis Disease Activity Index, and other quality‐of‐life measures. Upadacitinib was well tolerated, with no serious adverse events reported. The most common adverse event was upper respiratory tract infection (20%). Other mild adverse events included elevated alanine aminotransferase, nausea, mild headache, and sore throat. Conclusion: Upadacitinib demonstrated a rapid onset of action, significant efficacy, and a favorable safety profile in the treatment of SAPHO syndrome, supporting its potential as a therapeutic option in clinical practice.
- 28 August 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70825
Efficacy and Safety Assessment of Upadacitinib for SAPHO Syndrome: A Retrospective Study of 35 Patients
Objective: This study aimed to evaluate the efficacy and safety of upadacitinib administered over a short‐term period in patients with SAPHO syndrome. Methods: In this 12‐week retrospective observational study, eligible SAPHO syndrome patients diagnosed within the past year and treated with upadacitinib were enrolled. Efficacy was assessed using the Ankylosing Spondylitis Disease Activity Score based on C‐reactive protein (ASDAS‐CRP) and the Palmoplantar Pustulosis Area and Severity Index (PPPASI). Safety was evaluated based on the incidence of adverse events during the treatment period. Results: A total of 35 eligible patients were included. Both ASDAS‐CRP and PPPASI scores decreased rapidly by Week 4 (−1.01 and −11.41, respectively; both p < 0.001) and showed further significant improvements at Week 12 (−1.50 and −14.69, respectively; both p < 0.001) compared to baseline. Similar improvements were observed in the Visual Analogue Scale for overall musculoskeletal pain, the Bath Ankylosing Spondylitis Disease Activity Index, and other quality‐of‐life measures. Upadacitinib was well tolerated, with no serious adverse events reported. The most common adverse event was upper respiratory tract infection (20%). Other mild adverse events included elevated alanine aminotransferase, nausea, mild headache, and sore throat. Conclusion: Upadacitinib demonstrated a rapid onset of action, significant efficacy, and a favorable safety profile in the treatment of SAPHO syndrome, supporting its potential as a therapeutic option in clinical practice.
- 13 April 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (4) , e70643
Case Report: The First Case of Paradoxical Skin Lesions Induced by Xeligekimab in a Patient With SAPHO Syndrome
- 13 April 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (4) , e70643
Case Report: The First Case of Paradoxical Skin Lesions Induced by Xeligekimab in a Patient With SAPHO Syndrome
- 17 November 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (1) , 197-205
Physicians' perspectives on the diagnosis and treatment of adult SAPHO syndrome: a cross-sectional study from China
Objective To investigate the practices of doctors in the diagnosis and treatment of adult SAPHO syndrome. Methods A cross-sectional study was conducted by distributing online questionnaires to physicians across five hospitals, specifically targeting departments involved in the diagnosis and treatment of adult SAPHO syndrome, including rheumatology, dermatology, and orthopedics. Results A total of 103 clinical physicians participated in the survey.The three most commonly observed clinical features of adult SAPHO syndrome were elevated ESR and CRP (82/84), focal swelling and fever (73/84), and new lesions found on imaging (70/84). The primary diagnostic tools utilized were Whole body bone imaging (76.2%) and CT scans (60.1%), with less frequent use of MRI (22.6%) and positron emission tomography-computed tomography (PET-CT) (9.6%). Notably, only 14% of physicians reported never performing disease activity monitoring. Nearly all respondents (98%) selected nonsteroidal anti-inflammatory drugs (NSAIDs) as the first-line treatment. Additionally, 81% of physicians opted for target synthetic disease-modifying antirheumatic drugs (tsDMARDs), 78.6% for steroids, 71.4% for biological disease-modifying antirheumatic drugs (bDMARDs), 66.7% for conventional synthetic disease-modifying antirheumatic drugs (csDMARDs, and only 18.5% chose bisphosphonates (pamidronate and zoledronate). Conclusion While Whole body bone imaging and CT scans are widely used for the early diagnosis of adult SAPHO syndrome, there is a gap in the utilization of MRI and the practice of disease activity monitoring. Physicians prefer commonly used rheumatic drugs, but there remains limited application of bisphosphonates. Highlight • Our study first systematically investigated Chinese physicians' perspectives on the diagnosis and treatment of adult SAPHO syndrome. • We pointed out that the utilization of imaging tools (such as MRI) and bisphosphonates was low, suggesting that the diagnostic strategy needs to be optimized. • This study may aid the research of SAPHO syndrome at home and abroad, providing references.
- 17 November 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (1) , 197-205
Physicians' perspectives on the diagnosis and treatment of adult SAPHO syndrome: a cross-sectional study from China
Objective To investigate the practices of doctors in the diagnosis and treatment of adult SAPHO syndrome. Methods A cross-sectional study was conducted by distributing online questionnaires to physicians across five hospitals, specifically targeting departments involved in the diagnosis and treatment of adult SAPHO syndrome, including rheumatology, dermatology, and orthopedics. Results A total of 103 clinical physicians participated in the survey.The three most commonly observed clinical features of adult SAPHO syndrome were elevated ESR and CRP (82/84), focal swelling and fever (73/84), and new lesions found on imaging (70/84). The primary diagnostic tools utilized were Whole body bone imaging (76.2%) and CT scans (60.1%), with less frequent use of MRI (22.6%) and positron emission tomography-computed tomography (PET-CT) (9.6%). Notably, only 14% of physicians reported never performing disease activity monitoring. Nearly all respondents (98%) selected nonsteroidal anti-inflammatory drugs (NSAIDs) as the first-line treatment. Additionally, 81% of physicians opted for target synthetic disease-modifying antirheumatic drugs (tsDMARDs), 78.6% for steroids, 71.4% for biological disease-modifying antirheumatic drugs (bDMARDs), 66.7% for conventional synthetic disease-modifying antirheumatic drugs (csDMARDs, and only 18.5% chose bisphosphonates (pamidronate and zoledronate). Conclusion While Whole body bone imaging and CT scans are widely used for the early diagnosis of adult SAPHO syndrome, there is a gap in the utilization of MRI and the practice of disease activity monitoring. Physicians prefer commonly used rheumatic drugs, but there remains limited application of bisphosphonates. Highlight • Our study first systematically investigated Chinese physicians' perspectives on the diagnosis and treatment of adult SAPHO syndrome. • We pointed out that the utilization of imaging tools (such as MRI) and bisphosphonates was low, suggesting that the diagnostic strategy needs to be optimized. • This study may aid the research of SAPHO syndrome at home and abroad, providing references.
- 23 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70306
Does Gender Affect the Oxidative Stress Status of Rheumatoid Arthritis?
- 23 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70306
Does Gender Affect the Oxidative Stress Status of Rheumatoid Arthritis?
- 23 May 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (5) , e70294
Case Report: Can Chronic Relapsing Multifocal Osteomyelitis (CRMO) Be Combined With Hematologic Neoplasms?
- 23 May 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (5) , e70294
Case Report: Can Chronic Relapsing Multifocal Osteomyelitis (CRMO) Be Combined With Hematologic Neoplasms?
- 24 March 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (3) , e70193
Case Report: A Novel JAK‐1 Inhibitor, Upadacitinib, Successfully Treated 1 Case of Chronic Nonbacterial Osteomyelitis in Children
- 24 March 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (3) , e70193
Case Report: A Novel JAK‐1 Inhibitor, Upadacitinib, Successfully Treated 1 Case of Chronic Nonbacterial Osteomyelitis in Children
- 21 November 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (8) , e283-e285
Is tofacitinib monotherapy also effective for the treatment of Acrodermatitis continua of Hallopeau?
- 21 November 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (8) , e283-e285
Is tofacitinib monotherapy also effective for the treatment of Acrodermatitis continua of Hallopeau?
- 15 September 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (9) , e15335
Red cell distribution width/albumin ratio and mortality risk in rheumatoid arthritis patients: Insights from a NHANES study
Background: Despite the established negative regulatory effects observed in various diseases like cardiovascular disease and diabetes, the distinct impact of red cell distribution width (RDW) to albumin ratio (RAR) on mortality within the realm of rheumatoid arthritis (RA) remains obscure. This study sought to explore the relationship between RAR and mortality in RA patients.Methods: A cohort of 2151 adults with RA from the National Health and Nutrition Examination Survey (NHANES) spanning 2003–2016 was analyzed for RAR levels derived from red cell distribution width and albumin concentrations. Utilizing Cox regression analysis, Kaplan–Meier curves, and Restricted Cubic Spline (RCS) models, we assessed the association between RAR levels and RA mortality while adjusting for potential confounding variables.Results: Participants with higher RAR had a twofold to threefold increased risk of all‐cause (HR = 3.10, 95% CI: 2.26–4.24) and cardiovascular mortality (HR = 2.46, 95%CI: 1.26–4.79) versus lower RAR. Kaplan–Meier analysis revealed that the higher RAR group had a significantly lower survival rate compared to the lower RAR group for both all‐cause and cardiovascular mortality (both p < .0001), with a more pronounced effect observed for all‐cause mortality. Furthermore, the RCS‐fitted Cox regression model illustrated a nonlinear positive correlation between RAR levels and RA mortality.Conclusion: Overall, a higher RAR was associated with an increased risk mortality in RA patients. These findings underscore the potential of RAR as a prognostic biomarker in predicting outcomes in RA.
- 15 September 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (9) , e15335
Red cell distribution width/albumin ratio and mortality risk in rheumatoid arthritis patients: Insights from a NHANES study
Background: Despite the established negative regulatory effects observed in various diseases like cardiovascular disease and diabetes, the distinct impact of red cell distribution width (RDW) to albumin ratio (RAR) on mortality within the realm of rheumatoid arthritis (RA) remains obscure. This study sought to explore the relationship between RAR and mortality in RA patients.Methods: A cohort of 2151 adults with RA from the National Health and Nutrition Examination Survey (NHANES) spanning 2003–2016 was analyzed for RAR levels derived from red cell distribution width and albumin concentrations. Utilizing Cox regression analysis, Kaplan–Meier curves, and Restricted Cubic Spline (RCS) models, we assessed the association between RAR levels and RA mortality while adjusting for potential confounding variables.Results: Participants with higher RAR had a twofold to threefold increased risk of all‐cause (HR = 3.10, 95% CI: 2.26–4.24) and cardiovascular mortality (HR = 2.46, 95%CI: 1.26–4.79) versus lower RAR. Kaplan–Meier analysis revealed that the higher RAR group had a significantly lower survival rate compared to the lower RAR group for both all‐cause and cardiovascular mortality (both p < .0001), with a more pronounced effect observed for all‐cause mortality. Furthermore, the RCS‐fitted Cox regression model illustrated a nonlinear positive correlation between RAR levels and RA mortality.Conclusion: Overall, a higher RAR was associated with an increased risk mortality in RA patients. These findings underscore the potential of RAR as a prognostic biomarker in predicting outcomes in RA.
- 8 September 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (9) , e15336
SAPHO syndrome combined with optic neuritis: A case report
- 8 September 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (9) , e15336
SAPHO syndrome combined with optic neuritis: A case report